Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "Mark Peakman" Clear advanced filters

  • In this Opinion article, the authors suggest that more extensive use of laboratory measurements could help to expedite clinical trials of immunotherapy. They propose that surrogate end points could be used in place of clinical end points to determine drug safety, disease progression and therapeutic efficacy.

    • Bart O. Roep
    • Mark Peakman
    Reviews
    Nature Reviews Immunology
    Volume: 10, P: 145-152

  • T cell receptors are generated by somatic gene recombination, and are normally selected against autoreactivity. Here the authors show that CD4 T cells from patients with autoimmune type 1 diabetes have shorter TCRβ sequences, broader repertoire diversity, and more repertoire sharing than those from healthy individuals.

    • Iria Gomez-Tourino
    • Yogesh Kamra
    • Mark Peakman
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-15

  • Docking of T cell antigen receptors (TCRs) engaging complexes of peptide and major histocompatibility complex has shown the same diagonal orientation and polarity. A new study demonstrating that TCRs from regulatory T cells bind with reversed polarity challenges this dogma.

    • Mark Peakman
    • Andrew K Sewell
    News & Views
    Nature Immunology
    Volume: 16, P: 1105-1107

  • Complexities in sample handling, instrument setup and data analysis are barriers to the effective use of flow cytometry to monitor immunological parameters in clinical trials. The novel use of a central laboratory may help mitigate these issues.

    • Holden T Maecker
    • J Philip McCoy Jr
    • Jung-Hua Yeh
    Comments & Opinion
    Nature Immunology
    Volume: 11, P: 975-978

  • The need to translate basic research in the field of human immunology may be much more urgent, and the rewards potentially much greater, than is often acknowledged. Yet a commonly perceived coercion to undertake translational research may be unhelpful. Instead, we propose clear incentives for integrating key skill sets, together with achievable cultural adjustments in research and medicine that span training, recruitment and promotion.

    • Adrian C Hayday
    • Mark Peakman
    Comments & Opinion
    Nature Immunology
    Volume: 9, P: 575-580

  • There are multiple immune-based therapeutics available for some of the most prevalent autoimmune diseases, but for others, there are few or no approved immune therapies. This dichotomy poses discrete challenges. First, for diseases in which multiple therapy choices exist, a rational decision tree is required to select the best therapy. Second, we must devise new strategies for the autoimmune diseases that have the highest unmet clinical need. This commentary outlines new strategies for designing more efficient and selective approaches for immune therapy of autoimmune diseases.

    • Lawrence Steinman
    • Joan T Merrill
    • Mark Peakman
    Comments & Opinion
    Nature Medicine
    Volume: 18, P: 59-65